U.S. markets open in 3 hours 50 minutes
  • S&P Futures

    3,857.50
    +38.25 (+1.00%)
     
  • Dow Futures

    31,965.00
    +189.00 (+0.59%)
     
  • Nasdaq Futures

    12,545.25
    +248.00 (+2.02%)
     
  • Russell 2000 Futures

    2,236.10
    +35.30 (+1.60%)
     
  • Crude Oil

    65.83
    +0.78 (+1.20%)
     
  • Gold

    1,699.50
    +21.50 (+1.28%)
     
  • Silver

    25.76
    +0.50 (+1.96%)
     
  • EUR/USD

    1.1908
    +0.0055 (+0.46%)
     
  • 10-Yr Bond

    1.5960
    0.0000 (0.00%)
     
  • Vix

    24.69
    +0.03 (+0.12%)
     
  • GBP/USD

    1.3870
    +0.0048 (+0.35%)
     
  • USD/JPY

    108.7520
    -0.1490 (-0.14%)
     
  • BTC-USD

    54,014.86
    +4,373.43 (+8.81%)
     
  • CMC Crypto 200

    1,090.69
    +66.49 (+6.49%)
     
  • FTSE 100

    6,748.09
    +28.96 (+0.43%)
     
  • Nikkei 225

    29,027.94
    +284.69 (+0.99%)
     

Radius Health to Present at the 39th Annual J.P. Morgan Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
Radius Health Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Kelly Martin, President and CEO will present a virtual corporate update at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13 at 9:10 a.m. EST.

A live webcast of the presentation will be available by visiting the Investors section of Radius’ website at https://ir.radiuspharm.com/events-and-presentations. A replay of the webcast will be archived on Radius’ website for 90 days following the presentation.

About Radius

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics. Radius’ lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes the investigational use of abaloparatide injection for the treatment of men with osteoporosis, an investigational abaloparatide-patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer out-licensed to Menarini Group. For more information, please visit www.radiuspharm.com

Investor & Media Relations Contact:
Peter Schwartzman
Email: investor-relations@radiuspharm.com
Phone: (617) 583-2017